Clinical Trial Update: Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 study evaluating KM-001 for safety, tolerability, and potential efficacy in patients with Punctate Palmoplantar …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pachyonychia Congenita
• Punctate Palmoplantar Keratoderma Type

Drugs mentioned

• KM-001

Snippet

Sponsor: Kamari Pharma Ltd | Conditions: Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita | Phase 1 | Status: COMPLETED